Cargando…
P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study
INTRODUCTION: In this pilot study, we explored sleep biomarker risk probabilities for different neurodegenerative disorder (NDD) phenotypes across a spectrum of NDD patients, compared with controls. METHODS: We analyzed a cohort of patients with different NDD phenotypes who underwent in-home recordi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591739/ http://dx.doi.org/10.1093/sleepadvances/zpad035.107 |
_version_ | 1785124285579264000 |
---|---|
author | Levendowski, D Tsuang, D Neylan, T Walsh, C Lee-Iannotti, J Berka, C Mazeika, G Boeve, B St. Louis, E |
author_facet | Levendowski, D Tsuang, D Neylan, T Walsh, C Lee-Iannotti, J Berka, C Mazeika, G Boeve, B St. Louis, E |
author_sort | Levendowski, D |
collection | PubMed |
description | INTRODUCTION: In this pilot study, we explored sleep biomarker risk probabilities for different neurodegenerative disorder (NDD) phenotypes across a spectrum of NDD patients, compared with controls. METHODS: We analyzed a cohort of patients with different NDD phenotypes who underwent in-home recordings with Sleep Profiler, including Lewy body disease (LBD=20), Alzheimer’s disease dementia (AD=29), and isolated REM sleep behavior disorder (iRBD=19). Controls with an MMSE>28 (CG=61) and patients with Parkinson disease (PD=16) and mild-cognitive-impairment (MCI=41) also participated. We developed a machine-learning classifier that assigned NDD probabilities for LBD, AD, iRBD, and CG. The input variables included: time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Probabilities >50% were assigned “likely”, and for CG>=50% and a NDD group probability 20-50%, the assignment was normal “plus”. Probability assignments were then made for the NDD and CG groups, then further applied to the PD and MCI patient groups. RESULTS: The CG group participants were assigned Normal-Likely=74%, Normal+AD=11%, Normal+iRBD=5%, iRBD-Likely=5%, and AD-Likely=5%. LBD patient distributions were LBD-Likely=70%, iRBD-Likely=5%, AD-Likely=5%, Normal+LBD=5%, Normal+iRBD=5%, Normal+AD=5%, and Normal-Likely=5%. AD group distributions were AD-Likely=71%, LBD-Likely=4%, Normal+AD=14%, Normal+iRBD=4%, Normal-Likely=7%. iRBD patients were characterized with iRBD-Likely=37%, LBD-Likely=5%, AD-Likely=5%, Normal+iRBD=27%, Normal-Likely=26%. PD patients were assigned iRBD-Likely=29%, LBD-likely=14%, AD-Likely=14%, Normal+iRBD=21%, Normal+AD=7%, Normal-Likely=14%. MCI distributions were AD-Likely=45%, LBD-Likely=8%, iRBD-Likely=5%, Normal+AD=21%, Normal-Likely=13%. CONCLUSIONS: For LBD, AD and CG groups, correct risk assignments were >70% while gross misclassifications were <10%. Classification patterns for PD, MCI and iRBD were disbursed in a manner consistent with the range of severities expected in each group. |
format | Online Article Text |
id | pubmed-10591739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105917392023-10-24 P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study Levendowski, D Tsuang, D Neylan, T Walsh, C Lee-Iannotti, J Berka, C Mazeika, G Boeve, B St. Louis, E Sleep Adv Poster Discussion Presentations INTRODUCTION: In this pilot study, we explored sleep biomarker risk probabilities for different neurodegenerative disorder (NDD) phenotypes across a spectrum of NDD patients, compared with controls. METHODS: We analyzed a cohort of patients with different NDD phenotypes who underwent in-home recordings with Sleep Profiler, including Lewy body disease (LBD=20), Alzheimer’s disease dementia (AD=29), and isolated REM sleep behavior disorder (iRBD=19). Controls with an MMSE>28 (CG=61) and patients with Parkinson disease (PD=16) and mild-cognitive-impairment (MCI=41) also participated. We developed a machine-learning classifier that assigned NDD probabilities for LBD, AD, iRBD, and CG. The input variables included: time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Probabilities >50% were assigned “likely”, and for CG>=50% and a NDD group probability 20-50%, the assignment was normal “plus”. Probability assignments were then made for the NDD and CG groups, then further applied to the PD and MCI patient groups. RESULTS: The CG group participants were assigned Normal-Likely=74%, Normal+AD=11%, Normal+iRBD=5%, iRBD-Likely=5%, and AD-Likely=5%. LBD patient distributions were LBD-Likely=70%, iRBD-Likely=5%, AD-Likely=5%, Normal+LBD=5%, Normal+iRBD=5%, Normal+AD=5%, and Normal-Likely=5%. AD group distributions were AD-Likely=71%, LBD-Likely=4%, Normal+AD=14%, Normal+iRBD=4%, Normal-Likely=7%. iRBD patients were characterized with iRBD-Likely=37%, LBD-Likely=5%, AD-Likely=5%, Normal+iRBD=27%, Normal-Likely=26%. PD patients were assigned iRBD-Likely=29%, LBD-likely=14%, AD-Likely=14%, Normal+iRBD=21%, Normal+AD=7%, Normal-Likely=14%. MCI distributions were AD-Likely=45%, LBD-Likely=8%, iRBD-Likely=5%, Normal+AD=21%, Normal-Likely=13%. CONCLUSIONS: For LBD, AD and CG groups, correct risk assignments were >70% while gross misclassifications were <10%. Classification patterns for PD, MCI and iRBD were disbursed in a manner consistent with the range of severities expected in each group. Oxford University Press 2023-10-23 /pmc/articles/PMC10591739/ http://dx.doi.org/10.1093/sleepadvances/zpad035.107 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Sleep Research Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Discussion Presentations Levendowski, D Tsuang, D Neylan, T Walsh, C Lee-Iannotti, J Berka, C Mazeika, G Boeve, B St. Louis, E P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study |
title | P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study |
title_full | P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study |
title_fullStr | P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study |
title_full_unstemmed | P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study |
title_short | P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study |
title_sort | p022 sleep biomarker phenotyping of neurodegenerative disorders using artificial intelligence – a pilot study |
topic | Poster Discussion Presentations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591739/ http://dx.doi.org/10.1093/sleepadvances/zpad035.107 |
work_keys_str_mv | AT levendowskid p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy AT tsuangd p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy AT neylant p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy AT walshc p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy AT leeiannottij p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy AT berkac p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy AT mazeikag p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy AT boeveb p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy AT stlouise p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy |